Author(s): Martin David Harp
Key Takeaways
- TearCare System’s inclusion in TFOS DEWS III report validates its clinical efficacy and role in dry eye management.
- Data from studies such as SAHARA and OLYMPIA demonstrate TearCare’s superiority in improving tear breakup time and gland function.
- Cost-utility analysis results show TearCare’s cost-effectiveness and greater health utility over cyclosporine 0.05% for meibomian gland disease–associated dry eye.
Sight Sciences announced that its TearCare System has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology 1,2
This marks the first time that the TearCare System has been included in the TFOS DEWS III Management and Therapy Report.
Sam Garg, MD, professor of ophthalmology, director of cornea, cataract, and refractive surgery at Gavin Herbert Eye Institute, University of California, Irvine, commented on the inclusion, saying, “The recognition of the TearCare System as an interventional procedure within this publication is yet another strong validation of its clinical efficacy and integral role in patient care. The report itself is highly influential for clinicians refining treatment algorithms for dry eye.”
The TFOS DEWS III report has identified key research findings published since the 2017 TFOS DEWS II reports regarding sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design. The report was compiled to support evidence cited in the TFOS DEWS III Diagnostic Methodology and Management and Therapy reports and included input from 80 experts in 18 countries, according to TFOS.
For the TearCare System, the DEWS III report highlighted data from multiple published studies of the system that demonstrate its clinical efficacy, such as the 6-month SAHARA randomized controlled trial (RCT), the OLYMPIA RCT results, and an OLYMPIA subanalysis. In the 6-month SAHARA results, it was demonstrated that 2 TearCare System treatments were clinically superior in improving tear breakup time and multiple measures of gland function and were noninferior in Ocular Surface Disease Index (OSDI) results compared with twice-daily Restasis for the treatment of dry eye disease (DED).
The OLYMPIA RCT results showed that a single TearCare treatment significantly alleviated the signs and symptoms of DED in individuals, while the subanalysis showed that patients with more severe disease had significantly greater improvements in multiple symptoms of DED compared with LipiFlow.
Read more: https://shorturl.at/iYOrM
Source: Ophthalmology Times